Skip to main content

Table 2 Baseline characteristics of patients participating in the ATTAIN, ASSURE, ARRIVE, and ACTION studies who were taking one csDMARD in combination with abatacept

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

  ABA + MTX ABA + HCQ ABA + SSZ ABA + AZA ABA + LEF
ATTAIN cohort (n = 175) (n = 11) (n = 10) (n = 4) (n = 17)
 Female, n (%) 140 (80) 8 (73) 7 (70) 3 (75) 14 (82)
 Age (years) 52.85 (11.79) 52.91 (15.02) 55.10 (14.29) 63.50 (16.43) 50.76 (15.03)
 DAS28 (ESR) 6.9 (1.03) 7.0 (0.73) 6.6 (0.75) 7.3 (1.19) 7.2 (1.08)
 CDAI LDA/remission, n (%)
 RF positive, n (%) 129 (74) 9 (82) 7 (70) 1 (25) 12 (71)
 ACPA positive, n (%)
ASSURE cohort (n = 535) (n = 35) (n = 36) (n = 10) (n = 62)
 Female, n (%) 439 (82) 33 (94) 28 (78) 10 (100) 47 (76)
 Age (years) 52.19 (12.11) 54.77 (11.13) 53.89 (12.47) 51.10 (6.90) 54.76 (10.42)
 DAS28 (ESR)
 CDAI LDA/remission, n (%)
 RF positive, n (%)
 ACPA positive, n (%)
ARRIVE cohort (n = 490) (n = 49) (n = 32) (n = 30) (n = 65)
 Female, n (%) 405 (83) 43 (88) 22 (69) 25 (83) 53 (82)
 Age (years) 55.35 (12.32) 51.31 (11.54) 57.00 (13.69) 55.27 (11.30) 53.38 (11.4)
 DAS28 (CRP) 6.2 (0.72) 6.3 (0.81) 6.2 (0.75) 6.1 (0.74) 6.1 (0.72)
 CDAI LDA/remission, n (%)
 RF positive, n (%) 296 (60) 31 (63) 20 (63) 23 (77) 34 (52)
 ACPA positive, n (%)
ACTION cohort (n = 1182) (n = 57) (n = 45) (n = 15) (n = 253)
 Female, n (%) 926 (78) 45 (79) 35 (78) 9 (60) 204 (81)
 Age (years) 57.48 (12.31) 58.16 (13.16) 57.76 (11.89) 58.80 (14.11) 56.10 (13.59)
 DAS28 (ESR) 5.4 (1.25) 5.5 (1.19) 5.5 (1.32) 5.4 (1.44) 5.4 (1.37)
 CDAI LDA/remission, n (%) 31 (3.1) 1 (2.2) 2 (4.7) 1 (8.3) 14 (6.6)
 RF positive, n/N (%) 738/1027 (71.9) 33/49 (67.3) 27/37 (73.0) 7/11 (63.6) 142/205 (69.3)
 ACPA positive, n/N (%) 667/981 (68.0) 28/40 (70.0) 27/38 (71.1) 7/10 (70.0) 116/183 (63.4)
  1. Data are mean (standard deviation) unless otherwise indicated
  2. ABA abatacept, AZA azathioprine, ACPA anti-citrullinated protein antibody, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HCQ hydroxychloroquine, LDA low disease activity, LEF leflunomide, MTX methotrexate, RF rheumatoid factor, SSZ sulfasalazine